THIOBUTABARBITAL

Possibly Marketed Outside US

Details

Stereochemistry	UNKNOWN
Molecular Formula	C10H16N2O2S
Molecular Weight	228.311
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(C)C1(CC)C(=O)NC(=S)NC1=O

InChI

InChIKey=IDELNEDBPWKHGK-UHFFFAOYSA-N

InChI=1S/C10H16N2O2S/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)

HIDE SMILES / InChI

Molecular Formula	C10H16N2O2S
Molecular Weight	228.311
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13217426 | https://www.ncbi.nlm.nih.gov/pubmed/13500903 | https://www.ncbi.nlm.nih.gov/pubmed/13991716 | http://www.sciencedirect.com/topics/neuroscience/thiobarbiturates

Thiobutabarbital is a barbiturate derivative invented in the 1950s. It has sedative, anticonvulsant and hypnotic effects, it is used in veterinary medicine for induction in surgical anaesthesia. Thiobutabarbital was formerly used as anesthetic Inactin. ‘Inactin’ (sodium thiobutabarbital) produces smooth induction of anaesthesia after intravenous administration and has a prolonged duration of action. It has variable analgesic activity.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
hexose transport 2 Target ID: GO:0008645 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7819247	Inhibitor 8297		1.0 mM [IC50]
hexose transport 2 Target ID: GO:0008645 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7819247	Inhibitor 8297		1.0 mM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19881310 https://www.ncbi.nlm.nih.gov/pubmed/13283294 http://www.sciencedirect.com/topics/neuroscience/thiobarbiturates	Primary		Approved 8429	Inactin Approved Use Unknown

PubMed

Title	Date	PubMed
Peripheral melatonin mediates neural stimulation of duodenal mucosal bicarbonate secretion.	2001 Aug	11518737
Enhanced intestinal motility influences absorption in anaesthetized rat.	2001 Jun	11442451
The influence of phosphodiesterase inhibitor, rolipram, on hemodynamics in lipopolysaccharide-treated rats.	2001 Mar	11325016
Role of endothelin ET(A)- and ET(B)-receptors in haemodynamic compensation following haemorrhage in anaesthetized rats.	2002 Feb	11861314
Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats.	2002 Jan	11799091
Chemoprophylaxis of transfusion-transmitted agents in labile blood components.	2002 Jul-Aug	12170320
Propofol anesthesia compared to awake reduces infarct size in rats.	2002 May	11981160
Oxytocin-induced renin secretion by denervated kidney in anaesthetized rat.	2002 Nov 15	12421653
Brevenal is a natural inhibitor of brevetoxin action in sodium channel receptor binding assays.	2004 Aug	15233378
Kidney function in mice: thiobutabarbital versus alpha-chloralose anesthesia.	2004 Oct	15549274
Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.	2004 Oct	15339864
The effect of brevenal on brevetoxin-induced DNA damage in human lymphocytes.	2005 Nov	15986201
The inhibition of CHO-K1-BH4 cell proliferation and induction of chromosomal aberrations by brevetoxins in vitro.	2006 Jul	16487644
Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: implication for targeting protein kinases in metabolic diseases.	2007 Jan 15	17055723
Vasodilator effect of nicorandil on retinal blood vessels in rats.	2007 Jul	17525845
Low-dose candesartan improves renal blood flow and kidney oxygen tension in rats with endotoxin-induced acute kidney dysfunction.	2008 Aug	18091574
Reversal of high pancreatic islet and white adipose tissue blood flow in type 2 diabetic GK rats by administration of the beta3-adrenoceptor inhibitor SR-59230A.	2009 Aug	19491297
Resistin increases islet blood flow and decreases subcutaneous adipose tissue blood flow in anaesthetized rats.	2009 Feb	18715288

Patents

Sample Use Guides

In Vivo Use Guide

Male Wistar rats (8 to 10 weeks old) were anesthetized with thiobutabarbital (120 mg/kg, intraperitoneally (i.p.)).

Route of Administration: Intraperitoneal

In Vitro Use Guide

Thiobutabarbital inhibits hexose transport in cultured 3T3-C2 cells with IC50 value of 1.0 mM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:34:46 GMT 2023` Edited by `admin` on `Fri Dec 15 16:34:46 GMT 2023`
Record UNII	2N0251U7JH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

THIOBUTABARBITAL

Common Name

English

5-ETHYL-5-(1-METHYLPROPYL)-2-THIOBARBITURIC ACID

Systematic Name

English

Thiobutabarbital [WHO-DD]

Common Name

English

5-SEC-BUTYL-5-ETHYL-2-THIOXODIHYDROPYRIMIDINE-4,6(1H,5H)-DIONE

Systematic Name

English

THIOBUTABARBITAL [MI]

Common Name

English

NSC-32372

Code

English

5-ETHYLDIHYDRO-5-(1-METHYLPROPYL)-2-THIOXO-4,6(1H,5H)-PYRIMIDINEDIONE

Systematic Name

English

5-SEC-BUTYL-5-ETHYL-2-THIOBARBITURIC ACID

Systematic Name

English

THIOBUTABARBITAL [VANDF]

Common Name

English

THIBUTABARBITAL

Common Name

English

NSC-27685

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C67084